Suppr超能文献

Cathasept 管锁预防隧道式血液透析导管相关感染的多中心随机对照研究。

Cathasept Line Lock and Microbial Colonization of Tunneled Hemodialysis Catheters: A Multicenter Randomized Controlled Trial.

机构信息

Doncaster & Bassetlaw Hospitals NHS Foundation Trust, Doncaster Royal Infirmary, Doncaster, South Yorkshire, United Kingdom.

Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.

出版信息

Am J Kidney Dis. 2015 Dec;66(6):1015-23. doi: 10.1053/j.ajkd.2015.04.047. Epub 2015 Jun 30.

Abstract

BACKGROUND

Catheter-related bloodstream infections (CRBSIs) cause morbidity and mortality in hemodialysis (HD) patients. Cathasept (tetra-sodium EDTA) solution has antimicrobial and anticoagulant activities.

STUDY DESIGN

Multicenter prospective randomized controlled study.

SETTING & PARTICIPANTS: 117 maintenance HD patients with confirmed uncolonized tunneled HD catheters from 4 HD centers.

INTERVENTION

Patients were randomly assigned to receive Cathasept 4% locks (Cathasept group) or stayed with heparin 5,000 U/mL locks (heparin group), filled thrice weekly according to catheter lumen volume until the catheter was removed or for a maximum of 8 months.

OUTCOMES

Primary outcome was clinically significant microbial colonization of the catheter, defined as a through-catheter quantitative blood culture yielding ≥ 1,000 colony-forming units/mL of bacteria or yeast. Secondary outcomes included CRBSI rate, catheter patency, and biomarkers of inflammation and anemia.

MEASUREMENTS

Weekly through-catheter quantitative blood culture, high-sensitivity C-reactive protein fortnightly, and full blood count and ferritin monthly.

RESULTS

Incidence rates of catheter colonization were 0.14/1,000 catheter-days in the Cathasept group and 1.08/1,000 catheter-days in the heparin group (incidence rate ratio [IRR], 0.13; 95% CI, 0.003-0.94; P=0.02). CRBSI rates were 0.28/1,000 catheter-days in the Cathasept group and 0.68/1,000 catheter days in the heparin group (IRR, 0.40; 95% CI, 0.08-2.09; P=0.3). The proportion of dialysis sessions with achieved prescribed blood flow rate was significantly lower in the Cathasept group (66.8% vs 75.3%; P<0.001), with more patients requiring thrombolytic locks or infusions to maintain catheter patency (22 vs 9; P=0.01). Mean high-sensitivity C-reactive protein level was 11.6±5.3 (SE) mg/L lower for patients in the heparin group (P=0.03). Anemia marker levels were similar in both groups.

LIMITATIONS

Study was underpowered to assess effect on CRBSI, terminated early due to slow recruitment, and not double blinded.

CONCLUSIONS

Cathasept significantly reduced tunneled hemodialysis catheter colonization, but the reduction in CRBSIs was not statistically significant, and it was associated with more thrombotic complications. Its safety profile was comparable to heparin lock solution.

摘要

背景

导管相关血流感染(CRBSI)会导致血液透析(HD)患者发病和死亡。Cathasept(四钠 EDTA)溶液具有抗菌和抗凝活性。

研究设计

多中心前瞻性随机对照研究。

设置和参与者

4 个 HD 中心的 117 名维持性 HD 患者,均确诊为未定植隧道式 HD 导管。

干预措施

患者被随机分配接受 Cathasept 4%锁(Cathasept 组)或肝素 5000U/mL 锁(肝素组),根据导管腔体积每周填充 3 次,直至导管拔出或最长 8 个月。

结局

主要结局为导管的临床显著微生物定植,定义为通过导管定量血培养产生≥1000 菌落形成单位/mL 的细菌或酵母。次要结局包括 CRBSI 发生率、导管通畅性以及炎症和贫血生物标志物。

测量

每周通过导管定量血培养、每两周高敏 C 反应蛋白、每月全血细胞计数和铁蛋白。

结果

Cathasept 组导管定植发生率为 0.14/1000 导管日,肝素组为 1.08/1000 导管日(发病率比 [IRR],0.13;95%CI,0.003-0.94;P=0.02)。Cathasept 组 CRBSI 发生率为 0.28/1000 导管日,肝素组为 0.68/1000 导管日(IRR,0.40;95%CI,0.08-2.09;P=0.3)。Cathasept 组达到规定血流速度的透析次数比例明显较低(66.8%比 75.3%;P<0.001),需要溶栓锁或输注以维持导管通畅的患者比例更高(22 比 9;P=0.01)。肝素组的高敏 C 反应蛋白水平平均低 11.6±5.3(SE)mg/L(P=0.03)。两组贫血标志物水平相似。

局限性

该研究对 CRBSI 的影响评估力度不足,由于招募缓慢而提前终止,并且不是双盲研究。

结论

Cathasept 显著降低隧道式血液透析导管定植,但 CRBSI 发生率降低无统计学意义,且与更多血栓并发症相关。其安全性与肝素锁溶液相当。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验